Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA). The class action is on behalf of shareholders who purchased Verrica securities between May 28, 2021 and May 24, 2022, both dates inclusive (the “Class Period). Investors are hereby notified that they have until August 5, 2022 to move the Court to serve as lead plaintiff in this action.

What actions may I take at this time? If you suffered a loss and are interested in learning more about being a lead plaintiff, please contact Jim Baker ([email protected]) by email or phone at 619-814-4471. If emailing, please include a phone number.

To join this action, you can click or copy and paste the link below in a browser:

Verrica Pharmaceuticals Inc.

There is no cost or obligation to you.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that there were manufacturing deficiencies at the facility where Verrica’s contract manufacturer produced bulk solution for VP-102; (2) that these deficiencies were not remediated when Verrica resubmitted its NDA for VP-102 for molluscum; (3) that the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

A lead plaintiff will act on behalf of all other class members in directing the Verrica class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate…